<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2563">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946916</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00695-34</org_study_id>
    <nct_id>NCT04946916</nct_id>
  </id_info>
  <brief_title>Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease</brief_title>
  <acronym>Nfl_COG</acronym>
  <official_title>Validation of Serum Neurofilament Light Chain as a Biomarker to Differentiate Cognitive Impairment From Neurodegenerative or Psychiatric Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital le Vinatier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital le Vinatier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The validation of biomarkers allowing the discrimination of cognitive and behavioral&#xD;
      disorders of psychiatric origin from those of neurodegenerative origin would facilitate&#xD;
      diagnosis and improve patient management. Neurofilaments, which are markers of neuronal&#xD;
      lysis, appear to be a promising biomarker. In a previous preliminary study, the investigators&#xD;
      demonstrated significantly lower concentrations of neurofilaments in CSF of psychiatric&#xD;
      patients compared to neurodegenerative diseases.&#xD;
&#xD;
      The main objective of this study is to validate the plasma assay of neurofilament light chain&#xD;
      as a biomarker for the differential diagnosis of psychiatric or neurodegenerative cognitive&#xD;
      impairment. Other biomarkers of interest (Tau, TDP-43, GFAP and UCH-L1) will also be&#xD;
      analyzed.&#xD;
&#xD;
      A sub-part of this study will also focus on the retrospective analysis of the CSF/Plasma&#xD;
      correlations of the different biomarkers mentioned above from tube bottom samples taken in&#xD;
      routine care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred twenty participants will be included in this study&#xD;
&#xD;
        -  30 participants suffering from psychiatric disorders (bipolar disorder or schizophrenia)&#xD;
           without cognitive impairment&#xD;
&#xD;
        -  30 participants suffering from psychiatric disorders (bipolar disorder or schizophrenia)&#xD;
           with cognitive impairment&#xD;
&#xD;
        -  30 participants with a biological diagnosis of Alzheimer's disease&#xD;
&#xD;
        -  30 participants with frontotemporal dementia according to Rascosky's criteria&#xD;
&#xD;
      All the participants will perform cognitive, behavioral, and psychiatric evaluation and will&#xD;
      be have blood sample taken.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">October 22, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Four groups of participants will be recruited: participant with psychiatric condition without cognitive impairment, participants with psychiatric condition with cognitive impairment, participants with biological Alzheimer's disease, and participant with fronto-temporal dementia</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neurofilament light chain</measure>
    <time_frame>two months</time_frame>
    <description>serum neurofilament light chain concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total tau</measure>
    <time_frame>two months</time_frame>
    <description>serum tau protein concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFAP Glial fibrillary acidic protein</measure>
    <time_frame>two months</time_frame>
    <description>Serum GFAP concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurofilament heavy chain (pNF-h)</measure>
    <time_frame>two months</time_frame>
    <description>Serum neurofilament heavy chain (pNF-h) concentration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Alzheimer Disease</condition>
  <condition>FTD</condition>
  <arm_group>
    <arm_group_label>Participant with psychiatric condition without cognitive impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the psychiatric condition group without cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participant with psychiatric condition with cognitive impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the psychiatric condition group with cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria. To date, there are no clinical criteria for defining the dementia evolution of psychiatric disorders. The diagnosis of psychiatric disorder with cognitive involution is often made on the basis of subjective criteria or on the appreciation of health care teams. In the present study, cognitive involution will be defined by the occurrence of cognitive deterioration objectified by disturbed neuropsychological tests and the occurrence of progressive behavioral changes contrasting with the person's previous state and reported by the care team, a member of the family or by the patient himself. Cognitive involution must be accompanied by a decrease in autonomy with respect to the person's previous abilities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with biological Alzheimer's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alzheimer's disease with frontal, amnestic, language, and visual presentation with typical Alzheimer CSF according to the 2011 NIA-AA diagnostic criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with fronto-temporal dementia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probable or definite Fronto-temporal dementia, mostly behavioral variant of FTD (according to the diagnostic criteria for FTDb of Rascovsky, 2011) but Semantic Disease, Primary Progressive Non-Fluent Aphasia, Progressive Supra-Nuclear Palsy-DFT will be accepted if behavioral onset.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood sample taken</intervention_name>
    <description>Comparaison of Neurofilament light chain serum concentration between the arms</description>
    <arm_group_label>Participant with psychiatric condition with cognitive impairment</arm_group_label>
    <arm_group_label>Participant with psychiatric condition without cognitive impairment</arm_group_label>
    <arm_group_label>Patient with fronto-temporal dementia</arm_group_label>
    <arm_group_label>Patients with biological Alzheimer's disease</arm_group_label>
    <other_name>Cognitive tests and psychiatric questionnaires</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  haven given written consent&#xD;
&#xD;
        Participants with psychiatric conditions:&#xD;
&#xD;
          -  Schizophrenia (DSM-V criteria) with or without cognitive involution&#xD;
&#xD;
          -  Bipolar disorder (DSM-V criteria) with or without cognitive involution&#xD;
&#xD;
        Participants with neurodegenerative disease:&#xD;
&#xD;
          -  probable or definite FTD (Rascovsky criteria 2011)&#xD;
&#xD;
          -  Biological Alzheimer's disease with typical CSF (NIA-AA 2011)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uninterviewable patient and/or missing history&#xD;
&#xD;
          -  History of recent or previous head trauma with loss of consciousness&#xD;
&#xD;
          -  History of ischemic or hemorrhagic stroke&#xD;
&#xD;
          -  Chronic alcoholism / chronic drug use&#xD;
&#xD;
          -  Progressive somatic pathology / severe metabolic disorder / poorly controlled epilepsy&#xD;
&#xD;
          -  Age &lt; 45 years&#xD;
&#xD;
          -  Age &gt; 80 years&#xD;
&#xD;
          -  Electroconvulsive therapy for less than 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel DOREY, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH le Vinatier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorey Jean-Michel, MD,PHD</last_name>
    <phone>0437915249</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-michel.dorey@ch-le-vinatier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SARTELET lydie</last_name>
    <phone>0437915531</phone>
    <phone_ext>+33</phone_ext>
    <email>lydie.sartelet@ch-le-vinatier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Le Vinatier</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69678</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel DOREY, MD, PHD</last_name>
      <phone>04 37 91 51 00</phone>
      <email>jean-michel.dorey@ch-le-vinatier.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel DOREY, md, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL Consultation mémoire Neurologique -Hôpital Neurologique</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maïté Formaglio, PH</last_name>
      <phone>04.72.35.76.62</phone>
      <phone_ext>+33</phone_ext>
      <email>maite.formaglio@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>October 3, 2022</last_update_submitted>
  <last_update_submitted_qc>October 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dementia</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Clinical and biological IPD</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>4 years</ipd_time_frame>
    <ipd_access_criteria>all criterias</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

